Neurology News

Linus Health announced a collaboration with Goizueta Institute @Emory Brain Health and The Seavey Clinic at Emory Healthcare to implement digital cognitive assessments in primary care for early detection of Alzheimer’s disease.

About three in 10 adults with chronic pain who live in states with medical cannabis laws reported using cannabis to manage their pain, according to researchers, highlighting the need for more research on the subject.

High levels of patient engagement with nurse navigators after hospitalization for hemorrhagic stroke led to less disability and lower readmission rates after 90 days, according to research presented at International Stroke Conference.

While the biggest event of the sporting world is behind us for 2023, many former players are still suffering from the after effects of their own pursuit of the Lombardi Trophy.

Butylphthalide improved 90-day clinical outcomes in those with acute ischemic stroke who also received IV recombinant tissue plasminogen activator and/or endovascular treatment, per research presented at International Stroke Conference.

Residential exposure to traffic noise was linked to an increased risk for tinnitus, a finding that researchers said adds to the evidence of traffic noise as a growing health burden.

Black and Hispanic patients were less likely to be treated for stroke complications than their white counterparts, particularly treatment of arousal, spasticity and mood, per data presented at the International Stroke Conference.

Residents of “food swamp” communities, which have a higher prevalence of fast-food options than healthy options, may be at increased risk for incident stroke, according to research presented at the International Stroke Conference.

With a rising number of clinical studies demonstrating the potential benefits of psychedelic treatments for a wide range of behavioral health conditions, insurance plan provider Enthea aims to expand employer funding for these services.

Amylyx Pharmaceuticals Inc. announced completion of enrollment for a global, phase 3 clinical trial of AMX0035, an oral, fixed-dose medication for ALS.